Orphan drug chart 6
Orphan drug chart 7
Bristol-Myers Squibb’s Opdivo
approved for multiple myeloma &
Hodgkin’s lymphoma, and designated for hepatoma, glioblastoma,
small cell lung cancer and oesophageal cancer is set to be a distant second with $9.1B in worldwide sales.
[See orphan drug charts 6 & 7]
2022: TOP 20 ORPHAN R&D
PRODUCTS BASED ON NPV
Axicabtagene Ciloleucel will be
the World’s Most Valuable R&D
Kite Pharma’s Anti-CD19 chimeric antigen receptor (CAR) T cell
therapy in development for Non-Hodgkin’s lymphoma, is the world’s
most promising R&D orphan drug,
with an NPV of $7.9B. The top
three ranked products account for
19% of the total orphan NPV.
Of the products in R&D, eight are
classed as being developed in-house or having been in-licensed.
The remaining four products were
acquired through a company acquisition.
[See orphan drug charts 8 & 9]
Note: Forecast based on a single broker model. Sales represent company
reported sales where available, otherwise based on an average of equity
Worldwide sales represent sales for all indications. All sales analysis based
on EvaluatePharma®’s clean “Orphan” sub-set of products, as defined above
in Methodology on Classifying an Orphan Drug.